Non-selective pan-HDAC inhibitors panobinostat (LBH589) and belinostat (PXD101) have been approved by the U.S. Food and Drug Administration (FDA) for use in patients with multiple myeloma (MM) [5] and relapsed or refractory peripheral T-cell lymphoma [6], respectively. Here, HDAC9 is linked to plasma cell myeloma.